Business Wire

SOFINNOVA-PARTNERS

12.2.2020 08:02:09 CET | Business Wire | Press release

Share
Robert Carroll Joins Sofinnova Partners as Head of Investor Relations

Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan, announced today that it has appointed Robert Carroll as Partner, Head of Investor Relations. He will lead the firm’s fundraising and investor relations team and brings a dedicated focus to supporting and growing Sofinnova Partners’ investor base.

Dr. Carroll has a decade of experience working with institutional investors and raising capital for alternative assets. Prior to joining Sofinnova Partners, he helped establish and co-lead PwC's Global Fundraising Advisory Platform. Previously, Dr. Carroll worked at Mercury Capital Advisors, a global private fundraising and investment advisory firm, where he supported the needs of institutional investors and successfully raised capital across the alternative asset spectrum.

Prior to his career in private placement, Dr. Carroll, who holds a Ph.D. in Chemistry from University College London, worked as a principal scientist and project lead at Pfizer, developing pharmaceutical assets from discovery to pre-clinical and into clinical trials. He also held positions at GlaxoSmithKline and Eli Lilly.

“We are thrilled to have Rob on board, and to be able to bring his deep scientific and financial experience to the helm of our investor relations,” said Antoine Papiernik, Managing Partner and Chairman of the firm. “Rob’s hire reflects the firm’s broader expansion and thoughtful, strategic growth,” he added. Mr. Papiernik said the company has more than €2 billion under management and that €1 billion has been raised in the last four years, while its team has continued to grow steadily.

Dr. Carroll said “Sofinnova Partners continues to be a pioneer across the life sciences value chain with the recent addition of several new fund strategies, from acceleration to later-stage, and dedicated vehicles for gene and cell therapies, as well as industrial biotechnology. My priority will be to communicate the value our strategies can bring to the portfolios of our investors.”

Dr. Carroll completed his post-doctoral research at Brock University in Canada, with a focus on the semi-synthesis of morphine and its analogues. This work was carried out in collaboration with Noramco (then a part of Johnson & Johnson) and is the subject of a number of patents.

About Sofinnova Partners

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.

For more information, please visit: www.sofinnovapartners.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 13:00:00 CEST | Press release

Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415938477/en/ Photo credit: Jos Schmid, Photographer

tesa Selects Kinaxis as the Digital Backbone for Global Integrated Business Planning Transformation27.4.2026 13:00:00 CEST | Press release

Kinaxis Maestro™ platform to serve as the foundation for a multi‑year transformation to resilient, globally orchestrated planning ecosystem Kinaxis® (TSX: KXS), a global leader in end‑to‑end supply chain orchestration, today announced that tesa SE, a global manufacturer of adhesive tapes and self-adhesive product solutions, has selected the Kinaxis Maestro™ platform as a core enabler of its global, multi‑year supply chain and integrated business planning (IBP) transformation. Following an extensive evaluation, tesa selected Kinaxis to support its evolution from regionally fragmented planning practices toward a centrally governed, globally orchestrated IBP operatingmodel. Kinaxis will support tesa in improving enterprise-wide transparency, strengthening resilience, and enabling faster, more informed decision making across an increasingly complex and volatile global supply chain network. With 130 years of innovation, tesa is one of the world’s leading manufacturers of adhesive tapes and

70% of Enterprise AI is Uncontrolled, Driving Hidden Risk, Cost and Slower ROI27.4.2026 10:00:00 CEST | Press release

Lenovo research highlights a growing AI execution gap as organizations struggle to control and operate AI across their environments AI is already being used across your organization, whether it has been formally approved or not. Employees are using AI with or without IT involvement, fueling the rise of ‘shadow AI’ across the enterprise, creating gaps in governance and control. This is no longer just an IT challenge. For Chief Information Security Officers, this shift is expanding the attack surface across devices, endpoints, and data flows, introducing unmanaged risk and increasing the likelihood of sensitive company data being exposed or accessed without proper controls. What this reveals is a growing AI execution gap: usage is accelerating, but control is not keeping pace. Based on a survey of 6,000 employees worldwide, Lenovo’s latest Work Reborn Report, Leading Your Workforce to Triumph with AI, finds that more than 70% of employees are using AI weekly, with up to one third operati

First Enterprise Quantum Computer Purchase in Japan: IQM to Deploy System to TOYO Corporation27.4.2026 08:00:00 CEST | Press release

First enterprise quantum computer purchase in Japan cements IQM's position as the global leader in deployed quantum computers The Radiance 20-qubit system will enable TOYO to explore various industry use cases, while advancing a hybrid quantum-HPC infrastructure. This will be the third quantum computer to be deployed by IQM in the Asia-Pacific region. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the purchase of its full-stack 20-qubit quantum computer by TOYO Corporation, marking the first enterprise quantum system deployment in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426053944/en/ (From Left): Toshiya Kohno, Representative Director, President and CEO of TOYO Corporation, and Jan Goetz, CEO & Co-founder of IQM Quantum Computers. The Radiance 20-qubit system will be made available in both on-premises and cloud environments and will be delivered by the end of 2

SAP and S3NS Accelerate Trusted Cloud Adoption in France With Thales as First Strategic Customer27.4.2026 08:00:00 CEST | Press release

Thales adopts SAP RISE private cloud edition on S3NS to transform its ERP (Enterprise Resource Planning) landscape and operationalize digital sovereignty at scale. By combining SAP’s enterprise applications and Business AI capabilities with S3NS’s trusted infrastructure, this partnership unlocks cloud adoption for highly regulated sectors, including public administration, aerospace and defense, and operators of vital and essential services. Thales (Euronext Paris: HO): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426644177/en/ Strategic partnership (c)S3NS A decisive step in scaling trusted cloud in Europe The strategic partnership between SAP and S3NS, the trusted cloud provider established by Thales and Google Cloud, will strengthen trusted cloud capabilities in France and support Europe’s growing demand for cloud business transformation. SAP RISE private cloud edition will be deployed by SAP Sovereign Cloud on S3NS’

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye